Celiac disease is a condition in which the small intestine is damaged by gluten, the storage protein of wheat and similar proteins in barley and rye. The disease can cause different symptoms such as diarrhea, bloating, abdominal pain and weight loss. The majority of patients respond to a gluten-free diet. However some patients (5-30%) have persistent symptoms and are considered to be poor responders to the diet. Bacterial overgrowth in the small intestine accounts for some of the refractory patients. This study seeks to determine if antibiotic therapy with rifaximin relieves the symptoms of patients who are poorly responsive to a gluten-free diet and whether this impacts their breath test results.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score
Timeframe: Baseline (week 0)
Week 2 Gastrointestinal Symptom Rating Scale (GSRS) Score
Timeframe: Week 2
Week 12 Gastrointestinal Symptom Rating Scale (GSRS) Score
Timeframe: Week 12